About Us

History

2022
  • 1 Confirmed third patient's complete response to treatment (CR) by EBViNT
2021
  • 10 Obtained approval by MFDS (Ministry of Food and Drug Safety) for indication expansion of EBViNT to solid cancer
  • 10 First patient dosed in EU101 Phase 1 clinical trial in Korea
  • 8 Completed dosing of first cohort of EU101 Phase 2 clinical trial in China
  • 7 First patient dosed in EU101 Phase 1 clinical trial in the United States
  • 6 Completed dosing of first cohort of EU101 Phase 1 clinical trial in China
  • 4 Signed CDMO agreement with Samsung Biologics for EU505 development and manufacturing
  • 4 Patent of MVR CAR-T granted from United States Patent and Trademark Office
  • 3 Signed CDMO agreement with Samsung Biologics for EU103 development and manufacturing
  • 2 Completed application for EU101 Phase 1/2 MFDS (Ministry of Food and Drug Safety) IND for advanced solid tumors
  • 1 Patent of EU103 granted from United States Patent and Trademark Office
  • 1 Obtained FDA clinical approval for EU101 Phase 1/2 study
2020
  • 12 Completed application for EU101 Phase 1/2 FDA IND for advanced solid tumors
  • 12 Moved head office to Ace Hansol Tower from Daeryung Techno-town 17th
  • 10 Selected by Ministry of SMEs and Startups subsidization program to develop ACE2 protein as a COVID-19 treatment
  • 9 Obtained NMPA (China) clinical approval for EU101 Phase 1study for advanced solid tumors
  • 9 Signed CRO agreement for EU101 FDA approval and clinical studies with Syneos Health
  • 8 Completed application for EU101 FDA Pre-IND
  • 5 Signed strategic partnership agreement (MOU) with Germany's Miltenyi Biotec for smart manufacturing processes
  • 4 Signed multi-project CDMO agreement for lentivirus production with GenScript
2019
  • 12 Patent of TCR T Cell Therapy granted from United States Patent and Trademark Office
  • 7 Patent of EU101 granted from IP Australia
  • 4 Signed cooperative research contract with Ulsan University Hospital to develop treatment materials for incurable diseases
  • 4 Signed CRO agreement with Parexel for entry into US FDA clinical trials for TCR T Cell Therapy
  • 3 Signed a multi-project CDO Master Service Agreement with Samsung BioLogics
  • 1 Patent of EU101 granted from United States Patent and Trademark Office
2018
  • 12 Listed on KOSDAQ
  • 11 Completed patents acquisition from the University of Ulsan
  • 10 Signed Co-Development Agreement with National Cancer Center
  • 9 MFDS (Ministry of Food and Drug Safety) approval of TCR T Cell therapy EBViNT Phase I/II clinical trial
  • 6 Selected as a participating company for KISTA (Korea Intellectual Property Center) IP-R&D project (Global IP Strategy Development for Technological Innovation)
  • 5 Passed the Technology Evaluation for listing on KOSDAQ
2017
  • 11 Selected as an Excellent Safety Management Laboratory
  • 9 Signed L/O and strategic investment agreements with Zhejiang Huahai Pharmaceuticals
  • 4 Completion of GMP plant and animal laboratory construction
2016
  • 10 Signed agreement with National Cancer Center for cooperation research of TCR T Cell therapy
  • 9 Moved head office to Gasan-dong (Daeryung Techno-town 17th)
  • 7 Signed agreement with National Cancer Center for cooperation research of TCR T Cell therapy
  • 3 Completed IP transfer from National Cancer Center
  • 2 Completed Korea Drug Development Fund project transfer
2015
  • 7 Established R&D Laboratory
  • 2 Established Eutilex Co., LTD
2014
  • 3 Completed EBViNT Phase 1 clinical study (no side effects, anti-cancer effect confirmation of EBV-positive tumors)
  • 3 MFDS (Ministry of Food and Drug Safety) approval of TERiNT Phase 1 clinical study & start of clinical trial
2012
  • 12 MFDS (Ministry of Food and Drug Safety) approval of WTiNT Phase 1 clinical study & start of clinical trial
2011
  • 4 MFDS (Ministry of Food and Drug Safety) approval of EBViNT Phase 1 clinical study & start of clinical trial
2010
  • 7 Development of human antibody therapeutics (humanized anti-4-1BB, anti-AITR, etc.)
2009
  • Establishment of standardized manufacturing process of anti-tumor CD8 TCR T Cell therapy at the National Cancer Center
2008
  • Established GMP facility at the National Cancer Center
~2008
  • Development of anti-tumor CD8 TCR T Cell therapy & antibody therapeutics, and implementation of various autoimmune disease-targeted preclinical studies